Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy
- PMID: 37517031
- DOI: 10.1007/s10528-023-10460-3
Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy
Abstract
Inflammatory breast cancer (IBC) is a rare and highly invasive form of breast cancer, renowned for its aggressive behavior, malignant capacity, and unfavorable prognosis. Despite considerable advancements in comprehending the underlying biology of IBC, the immune cell infiltration (ICI) profile in IBC remains inadequately elucidated. The current work endeavors to investigate the ICI characteristics of IBC and ascertain the pivotal immune cell subtypes and genes that impact its prognosis. The present study employed microarray data from the GEO database to demonstrate that IBC exhibited a lower abundance of activated mast cells (AMC) in comparison to non-inflammatory breast cancer (nIBC) or normal breast tissue (NBT). Additionally, the mRNA expression level of the gene polo-like kinase 5 (PLK5), which was correlated with AMC, was found to be lower in IBC relative to nIBC or NBT. Furthermore, this investigation provided compelling evidence indicating a potential association between a decreased mRNA expression level of PLK5 and a shorter progression-free survival in patients with breast cancer. The gene set enrichment analysis performed on PLK5 revealed that the gene expression in IBC was closely associated with diverse immune functions and pathways. Besides, a negative correlation has been established between PLK5 mRNA expression level and a majority of immune checkpoint-related genes, thereby suggesting the potential suitability of immunotherapy treatment for IBC. In summary, this study offers valuable insights into the ICI profile of IBC and identifies potential target PLK5 for improving its clinical management.
Keywords: Activated mast cells; Immune cell infiltration; Inflammatory breast cancer; Polo-like kinase 5.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.Mol Cancer Ther. 2016 Jul;15(7):1746-56. doi: 10.1158/1535-7163.MCT-15-0353. Epub 2016 Apr 19. Mol Cancer Ther. 2016. PMID: 27196778
-
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.Ann Oncol. 2014 Feb;25(2):358-65. doi: 10.1093/annonc/mdt496. Epub 2013 Dec 2. Ann Oncol. 2014. PMID: 24299959 Free PMC article.
-
Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.J Transl Med. 2015 May 1;13:138. doi: 10.1186/s12967-015-0492-2. J Transl Med. 2015. PMID: 25928084 Free PMC article.
-
Genomic profiling of inflammatory breast cancer: a review.Breast. 2014 Oct;23(5):538-45. doi: 10.1016/j.breast.2014.06.008. Epub 2014 Jul 4. Breast. 2014. PMID: 24998451 Review.
-
New Treatment Strategies for the Inflammatory Breast Cancer.Curr Treat Options Oncol. 2021 Apr 24;22(6):50. doi: 10.1007/s11864-021-00843-2. Curr Treat Options Oncol. 2021. PMID: 33893888 Review.
Cited by
-
Inflammatory breast cancer microenvironment repertoire based on DNA methylation data deconvolution reveals actionable targets to enhance the treatment efficacy.J Transl Med. 2024 Aug 5;22(1):735. doi: 10.1186/s12967-024-05553-5. J Transl Med. 2024. PMID: 39103878 Free PMC article.
References
-
- Adesoye T, Lucci A (2021) Current surgical management of inflammatory breast cancer. Ann Surg Oncol 28:5461–5467. https://doi.org/10.1245/s10434-021-10522-z - DOI - PubMed
-
- Alonso-Miguel D, Fiering S, Arias-Pulido H (2022) Proactive immunotherapeutic approaches against inflammatory breast cancer may improve patient outcomes. Cells 11:2850. https://doi.org/10.3390/cells11182850 - DOI - PubMed - PMC
-
- Balema W, Liu D, Shen Y et al (2021) Inflammatory breast cancer appearance at presentation is associated with overall survival. Cancer Med 10:6261–6272. https://doi.org/10.1002/cam4.4170 - DOI - PubMed - PMC
-
- Bertucci F, Boudin L, Finetti P et al (2021) Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. Oncoimmunology 10:1929724. https://doi.org/10.1080/2162402X.2021.1929724 - DOI - PubMed - PMC
-
- Chainitikun S, Saleem S, Lim B et al (2021) Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res 29:1–12. https://doi.org/10.1016/j.jare.2020.08.014 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical